BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BACKGROUND: Ameloblastoma in 66% of the cases harbor a somatic mutation of the “mitogen-activated protein kinase” signaling pathway (BRAF V600E). In V600E mutations, BRAF is in the permanent “on” state and relays the growth-promoting signals independently of the EGFR pathway. Therefore, mutant BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebeling, Marcel, Scheurer, Mario, Sakkas, Andreas, Pietzka, Sebastian, Schramm, Alexander, Wilde, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147738/
https://www.ncbi.nlm.nih.gov/pubmed/37115331
http://dx.doi.org/10.1007/s12032-023-01993-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147738/
https://www.ncbi.nlm.nih.gov/pubmed/37115331
http://dx.doi.org/10.1007/s12032-023-01993-z

Ejemplares similares